ElevateBio Achieves Sixth Consecutive Year of Revenue Growth Driven by Expansion of its Genetic Medicine Technology and Manufacturing Business …
– Achieved 98% manufacturing batch success rate at BaseCamp across cell therapy, viral vector, and mRNA
– Positioned U.S.-based biomanufacturing hub to supply genetic medicine products across North America, South America, Europe, Asia, and Australia
… [7394 chars]
Source: GlobeNewswire | Published: 2026-01-08T12:30:00Z
Credit: GlobeNewswire
